Bruton’s tyrosine kinase (BTK) inhibitors are increasingly used in untreated and previously treated chronic lymphocytic leukaemia (CLL) patients. Invasive fungal infections (IFI) were rarely observed in patients treated for CLL in the pre-BTK era. In this article, we describe two patients with CLL who developed an IFI during treatment with the BTK inhibitor ibrutinib. The atypical presentation and the serious course of this complication are described.

Immunocompromised patients, invasive fungal infections, tyrosine kinase inhibitors.
hdl.handle.net/1765/131386
The Netherlands Journal of Medicine
Department of Pediatrics

Dunbar, A., Joosse, M.E, Boer, F, Eefting, M., & Rijnders, B.J.A. (2020). Invasive fungal infections in patients treated with Bruton's tyrosine kinase inhibitors. The Netherlands Journal of Medicine, 78(5), 294–296. Retrieved from http://hdl.handle.net/1765/131386